步长制药董事长赵涛：加速布局生物医药疫苗产业新赛道

Core Viewpoint - The 2025 Hong Kong International Biotechnology Forum and Exhibition (BIOHK2025) highlighted the growing demand for healthcare and the importance of biotechnology innovation in addressing this need, particularly in the context of China's aging population [1][2] Company Insights - Bichang Pharmaceutical's Chairman Zhao Tao emphasized the significance of standardized cultivation of traditional Chinese medicine, core business layout, industry development trends, and international strategies during his keynote speech at the forum [1] - The company is actively constructing a collaborative development framework involving patented traditional Chinese medicine, biochemical drugs, and the broader health industry, aiming to accelerate its entry into the biopharmaceutical and vaccine sectors [1] Industry Trends - The demand for medical resources is expected to increase significantly due to the rising healthcare consumption needs of the elderly population in China, which is approximately three times that of the general population [1] - The Chinese government is prioritizing the development of biomedicine and innovative drugs, implementing multiple policies to empower the industry through technology transfer and capital flow [1]